Jazz Pharmaceuticals (JAZZ) Misses Q2 EPS by 17c; Issues Mixed Outlook
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/15/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- SanDisk upgraded at JPMorgan after investor day; shares climb
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Piper Jaffray Cuts Price Target on Jazz Pharmaceuticals (JAZZ) to $178 Following Mixed 2Q
August 10, 2016 8:27 AM EDTPiper Jaffray maintained an Overweight rating on Jazz Pharmaceuticals (NASDAQ: JAZZ), and cut the price target to $178.00 (from $188.00), following the company's 2Q earnings report. JAZZ reported a non-GAAP EPS of $2.63 compared to Street estimates of $2.78. Revenues of $381M, compared to Street estimates of $376M.
Analyst David Amsellem... More
